Benefiting Cutting-edge Cancer Therapy
Children whose cancers have relapsed used to have few options — but a world-class program at Children’s Hospital of Philadelphia is changing that. The Cancer Immunotherapy Program offers cellular immunotherapy, an investigative treatment option that harnesses a patient’s own immune cells to fight treatment-resistant forms of certain cancers.
CHOP doctors and researchers helped develop the first clinical trials for an immunotherapy known as chimeric antigen receptor (“CAR”) T-cell therapy for children and young adults with advanced acute lymphoblastic leukemia. Results from the clinical trial were impressive — complete remission in more than 90 percent of participants. In 2012, the Cancer Immunotherapy Program treated the first pediatric patient with highly active cell therapy. Patients are now cancer free five years after receiving CAR T-cell therapy — without receiving any additional cancer treatment — and leading normal lives.
CAR T-cell therapy is just one of the cutting-edge treatments available at Children’s Hospital. Clinicians and researchers continue to develop other immunotherapies that could boost the power of the body’s immune system, reprogram the patient’s own cells, and better target cancer cells. While immunotherapy is not a first-line treatment for most forms of pediatric cancer, it does offer hope to children with treatment-resistant disease and their families.
Your support of the Carousel Ball impacts children here and all over the world who benefit from discoveries like cancer immunotherapy. These breakthroughs are advancing the standard of care for pediatric patients, and moving us closer to personalized medicine that could help children worldwide.
About Children’s Hospital of Philadelphia
Every day, teams at Children’s Hospital of Philadelphia make breakthroughs that transform children’s lives. Since our founding in 1855 as the nation’s first children’s hospital, we have made extraordinary discoveries, trained generations of leaders, and advocated for children everywhere. Our pediatric research program, one of the largest in the country, has set a new standard for scientific innovation around the world. As a nonprofit charitable organization, we rely on the generous support of donors who are inspired by our work — and our mission.